Opportunities Preloader

Please Wait.....

Report

Global Antihyperlipidemic Drugs Market Report and Forecast 2024-2032

Market Report I 2023-09-08 I 160 Pages I EMR Inc.

Global Antihyperlipidemic Drugs Market Report and Forecast 2024-2032
Global Antihyperlipidemic Drugs Market Outlook
The global antihyperlipidemic drugs market was valued USD 12.9 billion in 2023 driven by the increasing prevalence of cardiovascular diseases, rising awareness of lipid management, and the aging population has led to market growth across the globe. The market size is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032 to achieve a value of USD 21.4 billion by 2032.
Antihyperlipidemic Drugs: Introduction
Antihyperlipidemic drugs, also known as lipid-lowering medications, are a class of pharmaceuticals used to manage and control elevated levels of lipids (fats) in the blood. These drugs are primarily used to treat conditions like hyper lipidaemia, which is characterized by abnormally high levels of cholesterol and triglycerides in the bloodstream. Elevated lipid levels can increase the risk of cardiovascular diseases, including heart attacks and strokes. Antihyperlipidemic drugs play a crucial role in preventing and managing cardiovascular diseases, which are among the leading causes of death worldwide. They help lower elevated lipid levels, reduce the risk of atherosclerosis (hardening and narrowing of the arteries), and improve overall cardiovascular health.
Key Trends in the Global Antihyperlipidemic Drugs Market
- Rising Awareness of Lipid Management: Greater awareness of the importance of lipid management and the consequences of elevated cholesterol levels is leading to more individuals seeking medical treatment. Healthcare providers are increasingly emphasizing cholesterol control.
- Expanding Aging Population: As the global population ages, the prevalence of cardiovascular risk factors, including hyperlipidemia, tends to increase. This demographic trend is contributing to sustained demand for antihyperlipidemic drugs.
- Shift Toward Combination Therapies: To achieve optimal lipid control, healthcare providers are increasingly prescribing combination therapies that include multiple classes of antihyperlipidemic drugs. This approach targets different aspects of lipid metabolism and offers more comprehensive treatment.
- Emerging Therapies: The development of novel lipid-lowering therapies, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, has provided additional options for individuals who do not adequately respond to traditional medications like statins.

Global Antihyperlipidemic Drugs Market Segmentation
The market can be categorised drug class, distribution channel, end user and region.
Market Breakup by Drug Class

- Statins
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- Combination

Market Breakup Disease by Distribution Channel

- Hospitals Pharmacies
- Retail Pharmacies
- Drug Stores
- E-Commerce

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global Antihyperlipidemic Drugs Market Overview
The global antihyperlipidemic drugs market is a significant segment within the pharmaceutical industry, driven by the increasing prevalence of cardiovascular diseases, rising awareness of lipid management, and the aging population. Antihyperlipidemic drugs play a vital role in managing and reducing the risk of heart-related conditions associated with elevated lipid levels. The global antihyperlipidemic drugs market is substantial and continues to grow. The prevalence of cardiovascular diseases and the need for lipid-lowering medications contribute to its expansion. The market's growth is influenced by various factors, including demographic trends, lifestyle changes, and advances in pharmaceutical research and development.
North America and Europe are prominent markets for antihyperlipidemic drugs due to their well-established healthcare infrastructure and high prevalence of cardiovascular diseases. Emerging markets in Asia Pacific, Latin America, and Africa are experiencing growth in demand as awareness of cardiovascular health increases. global antihyperlipidemic drugs market is significant and continues to expand due to the increasing burden of cardiovascular diseases worldwide. These medications are a cornerstone of lipid management and are used in various clinical settings to reduce cardiovascular risk and improve patient outcomes. The market is characterized by a range of drug classes and is influenced by factors such as advances in pharmaceutical research and changing demographics.
Key Players in the Global Antihyperlipidemic Drugs Market
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in global antihyperlipidemic drugs market are as follows:
- Bristol-Myers Squibb Company
- Merck & Co.
- AstraZeneca
- Mylan N.V
- Abbott
- Aparito Ltd.
- Amgen Inc.
- Daiichi Sankyo Company
- Pfizer Inc.
- Dr. Reddy's Laboratories Ltd
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

1Preface
1.1Objectives of the Study
1.2Key Assumptions
1.3Report Coverage - Key Segmentation and Scope
1.4Research Methodology
2Executive Summary
3Global Antihyperlipidemic Drugs Market Overview
3.1Global Antihyperlipidemic Drugs Market Historical Value (2017-2023)
3.2Global Antihyperlipidemic Drugs Market Forecast Value (2024-2032)
4Global Antihyperlipidemic Drugs Market Landscape
4.1Global Antihyperlipidemic Drugs: Developers Landscape
4.1.1Analysis by Year of Establishment
4.1.2Analysis by Company Size
4.1.3Analysis by Region
4.2Global Antihyperlipidemic Drugs: Product Landscape
4.2.1Analysis by Distribution Channel
4.2.2Analysis by Drug Class
4.2.3Analysis by Region
5Global Antihyperlipidemic Drugs Market Dynamics
5.1Market Drivers and Constraints
5.2SWOT Analysis
5.3Porter's Five Forces Model
5.4Key Demand Indicators
5.5Key Price Indicators
5.6Industry Events, Initiatives, and Trends
5.7Value Chain Analysis
6Global Antihyperlipidemic Drugs Market Segmentation
6.1Global Antihyperlipidemic Drugs Market by Drug Class
6.1.1Market Overview
6.1.2Statins
6.1.3PCSK9 Inhibitors
6.1.4Bile Acid Sequestrants
6.1.5Cholesterol Absorption Inhibitors
6.1.6Fibric Acid Derivatives
6.1.7Combination
6.2Global Antihyperlipidemic Drugs Market by Distribution Channel
6.2.1Market Overview
6.2.2Hospitals Pharmacies
6.2.3Retail Pharmacies
6.2.4Drug Stores
6.2.5E-Commerce
6.3Global Antihyperlipidemic Drugs Market by Region
6.3.1Market Overview
6.3.2North America
6.3.3Europe
6.3.4Asia Pacific
6.3.5Latin America
6.3.6Middle East and Africa
7North America Global Antihyperlipidemic Drugs Market
7.1Market Share by Country
7.2United States of America
7.3Canada
8Europe Global Antihyperlipidemic Drugs Market
8.1Market Share by Country
8.2United Kingdom
8.3Germany
8.4France
8.5Italy
8.6Others
9Asia Pacific Global Antihyperlipidemic Drugs Market
9.1Market Share by Country
9.2China
9.3Japan
9.4India
9.5ASEAN
9.6Australia
9.7Others
10Latin America Global Antihyperlipidemic Drugs Market
10.1Market Share by Country
10.2Brazil
10.3Argentina
10.4Mexico
10.5Others
11Middle East and Africa Global Antihyperlipidemic Drugs Market
11.1Market Share by Country
11.2Saudi Arabia
11.3United Arab Emirates
11.4Nigeria
11.5South Africa
11.6Others
12Regulatory Framework
12.1Regulatory Overview
12.1.1US FDA
12.1.2EU EMA
12.1.3INDIA CDSCO
12.1.4JAPAN PMDA
12.1.5Others
13Patent Analysis
13.1Analysis by Type of Patent
13.2Analysis by Publication year
13.3Analysis by Issuing Authority
13.4Analysis by Patent Age
13.5Analysis by CPC Analysis
13.6Analysis by Patent Valuation
13.7Analysis by Key Players
14Grants Analysis
14.1Analysis by year
14.2Analysis by Amount Awarded
14.3Analysis by Issuing Authority
14.4Analysis by Grant Application
14.5Analysis by Funding Institute
14.6Analysis by NIH Departments
14.7Analysis by Recipient Organization
15Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2Analysis by Trial Status
15.3Analysis by Trial Phase
15.4Analysis by Therapeutic Area
15.5Analysis by Geography
16Funding and Investment Analysis
16.1Analysis by Funding Instances
16.2Analysis by Type of Funding
16.3Analysis by Funding Amount
16.4Analysis by Leading Players
16.5Analysis by Leading Investors
16.6Analysis by Geography
17Partnership and Collaborations Analysis
17.1Analysis by Partnership Instances
17.2Analysis by Type of Partnership
17.3Analysis by Leading Players
17.4Analysis by Geography
18Supplier Landscape
18.1Bristol-Myers Squibb Company
18.1.1Financial Analysis
18.1.2Product Portfolio
18.1.3Demographic Reach and Achievements
18.1.4Mergers and Acquisitions
18.1.5Certifications
18.2Merck & Co.
18.2.1Financial Analysis
18.2.2Product Portfolio
18.2.3Demographic Reach and Achievements
18.2.4Mergers and Acquisitions
18.2.5Certifications
18.3AstraZeneca
18.3.1Financial Analysis
18.3.2Product Portfolio
18.3.3Demographic Reach and Achievements
18.3.4Mergers and Acquisitions
18.3.5Certifications
18.4Mylan N.V
18.4.1Financial Analysis
18.4.2Product Portfolio
18.4.3Demographic Reach and Achievements
18.4.4Mergers and Acquisitions
18.4.5Certifications
18.5Abbott
18.5.1Financial Analysis
18.5.2Product Portfolio
18.5.3Demographic Reach and Achievements
18.5.4Mergers and Acquisitions
18.5.5Certifications
18.6Aparito Ltd.
18.6.1Financial Analysis
18.6.2Product Portfolio
18.6.3Demographic Reach and Achievements
18.6.4Mergers and Acquisitions
18.6.5Certifications
18.7Amgen Inc.
18.7.1Financial Analysis
18.7.2Product Portfolio
18.7.3Demographic Reach and Achievements
18.7.4Mergers and Acquisitions
18.7.5Certifications
18.8Daiichi Sankyo Company
18.8.1Financial Analysis
18.8.2Product Portfolio
18.8.3Demographic Reach and Achievements
18.8.4Mergers and Acquisitions
18.8.5Certifications
18.9Pfizer Inc.
18.9.1Financial Analysis
18.9.2Product Portfolio
18.9.3Demographic Reach and Achievements
18.9.4Mergers and Acquisitions
18.9.5Certifications
18.10Dr. Reddy's Laboratories Ltd
18.10.1Financial Analysis
18.10.2Product Portfolio
18.10.3Demographic Reach and Achievements
18.10.4Mergers and Acquisitions
18.10.5Certifications
19Key Opinion Leaders (KOL) Insights (Additional Insight)
20Company Competitiveness Analysis (Additional Insight)
20.1Very Small Companies
20.2Small Companies
20.3Mid-Sized Companies
20.4Large Companies
20.5Very Large Companies
21Payment Methods (Additional Insight)
21.1Government Funded
21.2Private Insurance
21.3Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE